Mehran Bahraini

Mr. Mehran Bahraini


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Open access
PDF file
Akbar DorgalalehAkbar Dorgalaleh
Akbar Dorgalaleh
Emmanuel J FavaloroEmmanuel J Favaloro
Emmanuel J Favaloro
MBMehran Bahraini
Mehran Bahraini
FRFariba Rad
Fariba Rad
The prothrombin time (PT) represents the most commonly used coagulation test in clinical laboratories. The PT is mathematically converted to the international normalized ratio (INR) for use in monitoring anticoagulant therapy with vitamin K antagonists such as warfarin in order to provide test results that are adjusted for thromboplastin and instrument used. The INR is created using two major PT ‘correction factors’, namely the mean normal PT (MNPT) and the international sensitivity index (ISI). Manufacturers of reagents and coagulometers have made some efforts to harmonizing INRs, for example, by tailoring reagents to specific coagulometers and provide associated ISI values. Thus, two types of ISIs may be generated, with one being a ‘general’ or ‘generic’ ISI and others being reagent/coagulometer‐specific ISI values. Although these play a crucial role in improving INR results between laboratories, these laboratories reported INR values are known to still differ, even when laboratories use the same thromboplastin reagent and coagulometer. Moreover, ISI values for a specific thromboplastin can vary among different models of coagulometers from a manufacturer using the same method for clot identification. All these factors can be sources of error for INR reporting, which in turn can significantly affect patient management. In this narrative review, we provide some guidance to appropriate ISI verification/validation, which may help decrease the variability in cross laboratory reporting of INRs.

26 October 2021 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
MBMehran Bahraini
Mehran Bahraini
ADAkbar Dorgalaleh
Akbar Dorgalaleh
The cardinal pathology of coronavirus disease 2019 (COVID-19) is a primary infection of pulmonary tract cells by severe acute respiratory syndrome coronavirus 2, provoking a local inflammatory response, often accompanied by cytokine storm and acute respiratory distress syndrome, especially in patients with severe disease. Systemic propagation of the disease may associate with thrombotic events, including deep vein thrombosis, pulmonary embolism, and thrombotic microangiopathy, which are important causes of morbidity and mortality in patients with COVID-19. This narrative review describes current knowledge of the pathophysiological mechanisms of COVID-19-associated coagulopathy, with focus on prothrombotic changes in hemostatic mediators, including plasma levels of clotting factors, natural anticoagulants, components of fibrinolytic system, and platelets. It will also highlight the central role of endothelial cells in COVID-19-associated coagulopathy. This narrative review discusses also potential therapeutic strategies for managing thrombotic complications. Awareness by medical experts of contributors to the pathogenesis of thrombotic events in COVID-19 is imperative to develop therapeutics not limited to regular anticoagulants. Instituting cooperation among medical personnel and researchers may lessen this novel virus' impact now, and in the event of recurrence. Publication Date: 25 October 2021 (online) © 2021. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

10 July 2023 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
MBMehran Bahraini
Mehran Bahraini
AFAlieh Fazeli
Alieh Fazeli
ADAkbar Dorgalaleh
Akbar Dorgalaleh
The factor V Leiden (FVL) polymorphism is known as the most common inherited risk factor for venous thrombosis. In turn, FVL is the leading cause of an activated protein C resistance (APCR) phenotype, in which the addition of exogenous activated protein C to plasma does not result in the expected anticoagulant effect. In the routine laboratory approach to the formal diagnosis of FVL, an initial positive screening plasma-based method for APCR is often performed, and only if needed, this is followed by a confirmatory DNA-based assay for FVL. Multiple methods with accepted sensitivity and specificity for determining an APCR/FVL phenotype are commonly categorized into two separate groups: (1) screening plasma-based assays, including qualitative functional clot-based assays, for APCR, and (2) confirmatory DNA-based molecular assays, entailing several tests and platforms, including polymerase chain reaction-based and non-PCR-based techniques, for FVL. This review will describe the methodological aspects of each laboratory test and prepare suggestions on the indication of APCR and FVL testing and method selection.


29 June 2025
Verified
Book Chapter
Closed access
PDF file
AFAlieh Fazeli
Alieh Fazeli
MBMehran Bahraini
Mehran Bahraini
MSMahmood Shams
Mahmood Shams

11 October 2023 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
PDF file
MBMehran Bahraini
Mehran Bahraini
AFAlieh Fazeli
Alieh Fazeli
ADAkbar Dorgalaleh
Akbar Dorgalaleh
The affiliations of Mehran Bahraini and Akbar Dorgalaleh have been updated in the above article published in the Seminars in Thrombosis & Hemostasis (DOI: 10.1055/s-0043-1770773). The correct affiliations appear as above. Article published online: 25 October 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA